市場調查報告書
商品編碼
1561655
2024-2032 年按產品類型(試劑和消耗品、設備)、技術(色譜、免疫測定等)、最終用戶(實驗室、醫院、研究中心)和地區分類的血紅蛋白測試市場報告Hemoglobin Testing Market Report by Product Type (Reagents and Consumables, Equipment), Technology (Chromatography, Immunoassay, and Others), End-User (Laboratories, Hospitals, Research Centers), and Region 2024-2032 |
2023年,全球血紅素檢測市場IMARC Group達24億美元。
血紅蛋白測試可測量血液中紅血球 (RBC) 的數量或血紅蛋白的水平。血紅蛋白是紅血球中存在的一種蛋白質,它將氧氣輸送到器官並將二氧化碳輸送回肺部。醫生廣泛使用血紅蛋白測試作為常規檢查的一部分或診斷患者的嚴重疾病。如果測試顯示一個人體內的血紅蛋白水平低於正常水平,則表示他們的紅血球數量較低,並且容易出現貧血等疾病。如果紅血球數高於正常值,則可能是血液疾病的徵兆,也可能是由居住在高海拔地區、吸菸和脫水引起的。血紅蛋白檢測市場的主要最終用戶是醫學實驗室、醫院和研究中心。
貧血和糖尿病等慢性疾病的盛行率不斷上升是推動全球血紅素檢測市場的關鍵因素。 2018年,全球估計有4.9億人患有糖尿病。目前,人口老化加劇、不良飲食習慣、久坐生活方式和肥胖程度上升正在加劇糖尿病的流行。糖尿病患者需要定期接受血糖和 HbA1c 水平檢測,這推動了對此類檢測的需求。此外,各種健康保險政策下的血紅蛋白檢測優惠報銷等因素也促進了市場的成長。然而,在許多國家,醫療保險並不能全額報銷血紅蛋白檢測的費用,但透過部分支付和其他承保,消費者擴大採用定期和定期檢測來檢查和維護他們的整體健康狀況。此外,衛生基礎設施的改善、人均醫療保健支出的增加、對血液相關疾病的認知不斷提高、人口老化、技術進步等因素預計也將在未來幾年推動全球血紅蛋白檢測市場的發展。
The global hemoglobin testing market size reached US$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.4% during 2024-2032.
A hemoglobin test measures the count of red blood cells (RBC) or the level of hemoglobin in the blood. Hemoglobin is a type of protein present in the RBCs that carries oxygen to the organs and transports carbon dioxide back to the lungs. Hemoglobin tests are used extensively by doctors as a part of their routine check-ups or to diagnose a serious medical condition in the patient. If a test reveals that the hemoglobin level in an individual's body is lower than normal, it means that they have a low RBC count and are prone to disorders such as anemia. If the RBC count is higher than normal, it could be an indication for a blood disorder or can be caused by living at a high altitude, smoking and dehydration. The key end users of hemoglobin testing market are medical laboratories, hospitals and research centers.
An increasing prevalence of chronic disorders such as anemia and diabetes represent a key factor driving the global hemoglobulin testing market. In 2018, an estimated 490 Million people around the world suffered from diabetes. The prevalence of diabetes is currently being catalysed by an increasing ageing population, poor dietary habits, sedentary lifestyles and rising levels of obesity. Patients suffering from diabetes need to undergo tests to measure blood glucose and HbA1c levels regularly, driving the demand for such tests. Moreover, factors such as favourable reimbursement of hemoglobin testing under various health insurance policies is also catalyzing the growth of the market. However, in many countries, medical insurance doesn't fully reimburse the cost of hemoglobin testing, but with partial payment and other coverages, consumers are increasingly adopting regular and periodic tests in order to check and maintain their overall health. Furthermore, factors such as improving health infrastructure, increasing per capita expenditure on health care, rising awareness for blood-related ailments, ageing population, technological advancements, etc. are also projected to drive the global hemoglobin testing market in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobin testing market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on product type, technology, and end-user.
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Bio-Rad Laboratories, Danaher, EKF Diagnostics, F. Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, Alere, ACON Laboratories, ARKRAY, Bayer Medical Care, Daiichi Biotech, DiaSys Diagnostic Systems, Epinex Diagnostics, Erba Diagnostics, etc.